natgillin/translations-raw huggingface dataset:
AUC: ↓ 4% (↓ 32 to ↑ 34) Cmax: ↓ 5% (↓ 27 to ↑ 24)
AUC: ↓ 4 % (↓ 32 do ↑ 34) Cmax: ↓ 5 % (↓ 27 do ↑ 24) Cmin: n/i etinilestradiol:
Oral administration.
- Navodilo shranite.
Didanosine/Tenofovir disoproxil
Skupina dizoproksiltenofovirata
Uncommon side effects
Nezaznana učinkovina
rates of virological failure within several tested combinations for the treatment of HIV-1 infection.
Sočasna uporaba zmanjšanega odmerka didanozina (250 mg) in zdravljenje z dizoproksiltenofoviratom je bilo v več preizkušenih kombinacijah za zdravljenje okužbe z virusom HIV-1
+ Efavirenz/Emtricitabine/Tenofovir disoproxil (600 mg/200 mg/245 mg q.d.)
(400 mg enkrat dnevno) + efavirenz/emtricitabin/ dizoproksiltenofovirat (600 mg/200 mg/245 mg enkrat dnevno)
AUC: ↔ Cmax: ↓ 30%
AUC: ↔ Cmax: ↓ 30 % Cmin: N/V
ORAL CONTRACEPTIVES Norgestimate/Ethinyl oestradiol/Tenofovir disoproxil
norgestimat/etinilestradiol/
Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil, ledipasvir/sofosbuvir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Povečane koncentracije tenofovirja v plazmi zaradi sočasnega dajanja dizoproksiltenofovirata, sofosbuvirja/velpatasvirja/voksilapr evirja in darunavirja/ritonavirja lahko povečajo neželene učinke, povezane z dizoproksiltenofoviratom, vključno z motnjami delovanja ledvic.
HIV.
izpuščaj
Hepatitis C virus (HCV) antiviral agents Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.)
Protivirusna zdravila za zdravljenje hepatitisa C (HCV) ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno) + atazanavir/ritonavir (300 mg enkrat dnevno/100 mg enkrat dnevno) + emtricitabin/ dizoproksiltenofovirat (200 mg/245 mg enkrat dnevno)1
• joint or muscle aches
• bolečine v sklepih ali mišicah
Regular determination of resistance is therefore recommended.
Zato je priporočeno redno določanje rezistence.
Very rare (<1/10,000), not known (cannot be estimated from the available data)
Zelo redki (< 1/10000), neznano (iz razpoložljivih podatkov ni mogoče oceniti)
Adequate hydration must be ensured.
zagotoviti je treba ustrezno hidracijo.
It is advisable never to use several medicines at the same time without consulting your doctor first.
Nikoli ni priporočljivo jemati več zdravil hkrati, ne da bi se prej posvetovali z zdravnikom.
To be used immediately after the vial is opened.
Uporabite takoj po odprtju viale.
Furthermore, you should drink a sufficient amount of liquid (about 1.5 - 2 litres daily).
Poleg tega morate piti dovolj tekočine (približno 1,5-2 litra na dan);
The percentage of resistant strains can be subject to great local variation.
Odstotek rezistentnih sevov je lahko odvisen od velikih lokalnih variacij.
Therefore the bleeding time should be monitored.
Zato je treba čas krvavitve spremljati;
Use during pregnancy is contraindicated.
Uporaba med nosečnostjo je kontraindicirana.
• Mycobacerium tuberculosis test.
• preizkus za Mycobacerium tuberculosis.
• liver impairment in the past.
• jetrna okvara v preteklosti.
The treatment should be continued for at least three days after the signs of the infection have disappeared.
Zdravljenje je treba nadaljevati vsaj še tri dni po tem, ko izginejo simptomi.
This may increase the risk of methotrexate associated toxic reactions.
To lahko poveča tveganje za toksične reakcije, povezane z metotreksatom.
Sequential therapy can also be used.
Lahko se uporabi tudi sekvenčno zdravljenje.
These reactions occur more frequently when the infusion time is 30 minutes or less.
Te reakcije so pogostejše, kadar je čas infundiranja 30 minut ali manj.
The above-mentioned substances are converted by a specific enzyme (CYP1A2).
Zgoraj omenjene snovi presnavlja poseben encim (CYP1A2).
Further intravenous administration is not contraindicated unless the reactions reoccur or worsen.
Nadaljnje intravensko infundiranje ni kontraindicirano, razen če se reakcije pojavijo znova ali se poslabšajo.
Monitoring the level of active substance in the blood provides the most reliable basis for dose adjustment.
Spremljanje ravni zdravilne učinkovine v krvi je najzanesljivejša osnova za prilagajanje odmerka.
Before starting treatment - if you suffer or have suffered from one of the following diseases:
Pred začetkom zdravljenja - če imate ali ste imeli katero izmed naslednjih bolezni:
The recommended duration of treatment is 10 - 14 days.
Priporočeno trajanje zdravljenja je 10-14 dni.
For information on mixing with other solutions: see sections 6.2 and 6.6.
Za informacije o mešanju z drugimi raztopinami glejte poglavji 6.2 in 6.6.
• increased skin sensitivity to sunlight or UV light.
• povečana občutljivost kože za sončno svetlobo ali UV-svetlobo.
If a prolonged treatment is necessary, a reassessment of treatment should be done at 2 months at the latest.
Če je dolgotrajno zdravljenje nujno, je treba učinek zdravljenja oceniti najpozneje po 2 mesecih.
• If you are pregnant or wish to become pregnant
• če ste noseči ali želite zanositi;
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Po potrebi je treba poiskati nasvet strokovnjaka, kadar je lokalna prevalenca rezistence taka, da je uporaba zdravila vsaj pri nekaterih vrstah okužb vprašljiva.
• children under 5 years of age.
• otrocih, mlajših od 5 let.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Pozorni morate biti na uradne smernice za ustrezno uporabo antibiotikov.
Very rare: psychotic reactions (which may progress to self-endangering behaviour).
Zelo redki: psihotične reakcije (ki lahko napredujejo do samomorilskega vedenja).
In very rare cases these allergic reactions may lead to life-threatening shock.
V zelo redkih primerih lahko te alergijske reakcije povzročijo smrtno nevaren šok;
Average duration of treatment can be 4-6 weeks.
Povprečno trajanje zdravljenja je lahko 4 do 6 tednov.
Local reaction:
Lokalne reakcije:
However, if this is not possible the patient is recommended to use a sun-protection cream.
Če to ni mogoče, je treba bolniku svetovati uporabo kreme za zaščito proti soncu.
Lactic acid (E 270)
Mlečna kislina (E 270)
The following undesirable reactions have been observed:
Opazili so naslednje neželene učinke:
Other preclinical effects were observed only at exposures that were sufficiently in excess of the maximum human exposure so that concern for human safety is negligible.
Druge predklinične učinke so opazili samo pri izpostavljenosti, ki je bila bistveno večja od največje izpostavljenosti pri človeku, zato je skrb za varnost človeka zanemarljiva.
Pack sizes: 1.5 10 or 20 vials.
Velikosti pakiranj: 1, 5, 10 ali 20 vial.
Teratogenic effects have not been observed in animal experimental research.
V raziskavah na živalih niso opazili teratogenih učinkov.
This medicine may cause these side effects, particularly if you are older or take a medicine of the socalled steroid group, such as hydrocortisone.
To zdravilo lahko povzroči neželene učinke, zlasti če ste starejši ali če jemljete zdravila iz tako imenovane skupin steroidov, na primer hidrokortizon;
When photosensibility occurs the treatment must be discontinued.
Če se pojavi fotosenzitivnost, je treba zdravljenje prekiniti.
Your doctor will monitor you for signs of methotrexate overdose.
Zdravnik vas bo opazoval zaradi znakov prevelikega odmerjanja metotreksata;
Depression or psychoses lead to self-endangering behaviour in some cases.
V nekaterih primerih depresija in psihoze povzročajo samomorilsko vedenje.
This relatively high distribution volume indicates an effective tissue and fluid penetration.
Ta sorazmerno velik volumen porazdelitev kaže na učinkovito penetracijo v tkiva in tekočine.
Unless compatibility is proven, the solution for infusion should always be administered separately.
Če združljivost ni dokazana, je treba raztopino za infundiranje vedno dajati ločeno.
The enzyme DNA-gyrase plays a crucial role in this process.
Pri tem ima DNA-giraza ključno vlogo.
Amp-C producing Escherichia coli
ki proizvaja Amp-C Escherichia coli
These events were observed predominantly among patients with further risk factors for QTc prolongation.
Te učinke so opazili predvsem pri bolnikih z dodatnimi dejavniki tveganja za podaljšanje intervala QTc.
When undesirable effects on the central nervous system, like dizziness, occur, it is prohibited to drive a vehicle or to operate machines.
Kadar se pojavijo neželeni učinki na osrednje živčevje, kot je omotica, je prepovedano voziti ali upravljati stroje.
Up to now, no evidence has been found of an increased risk of congenital abnormalities or other undesirable effects following use of ciprofloxacin or other quinolones during the first trimester.
Do sedaj niso našli dokazov o povečanem tveganju za kongenitalne abnormalnosti ali druge neželene učinke po uporabi ciprofloksacina ali drugih kinolonov v prvem trimesečju.
The plasma protein binding of ciprofloxacin is situated between 16% and 28% and is not dependent on the concentration and pH (determined by means of ultrafiltration).
Vezava na beljakovine v plazmi je med 16 in 28 % ter ni odvisna od koncentracije in vrednosti pH (določena z ultrafiltracijo).
• local reactions after administration of this medicine.
• lokalne reakcije po uporabi zdravila.
Signs of anaemia are a feeling of weakness and in more severe cases breathlessness and pale skin.
Znaki anemije so občutek šibkosti in, v hujših primerih, zasoplost in bleda koža.
The patient should be monitored closely and treated symptomatically with supportive measures.
Bolnika je treba pozorno spremljati in mu nuditi simptomatsko zdravljenje ter podporne ukrepe.
• bone infections.
• okužbe kosti.
In this case the kidney function must be frequently (twice per week) monitored.
V tem primeru je treba delovanje ledvic spremljati redno (dvakrat na teden);
During or after treatment - if one of the following conditions occurs:
Med zdravljenjem in po njem - če se pojavi kateri koli od naslednjih znakov:
You should consult your doctor if you are pregnant or wish to become pregnant.
Povejte zdravniku, če ste noseči ali želite zanositi.
Species for which acquired resistance may be a problem Gram-positive aerobes
Vrste, pri katerih je pridobljena rezistenca lahko težava Grampozitivni aerobi:
• myastenia gravis (a particular type of muscle weakness).
• miastenija gravis (posebna vrsta mišične šibkosti).
If you are older than 65 years your doctor may prescribe you a dose based on your kidney function and severity of disease.
Če ste starejši od 65 let, vam lahko zdravnik predpiše odmerek na podlagi delovanja ledvic in stopnje bolezni.
Your doctor will check your renal function carefully.
Zdravnik bo pozorno pregledal vaše ledvice;
• certain lower respiratory tract infections including pneumonia
• nekatere okužbe spodnjih dihal, vključno s pljučnico;
In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/kg.
V pogojih ravnotežnega stanja je navidezni volumen porazdelitve ciprofloksacina med 1,7 in 2,7 l/kg.
With regard to the safety and use of ciprofloxacin in children, see also section 4.4
Za informacije o varnosti in uporabi ciprofloksacina pri otrocih, glejte tudi poglavje 4.4;
The frequency of side effects is classified into the following categories: Very common in more than 1 in 10 patients
Pogostnost neželenih učinkov je razvrščena na naslednji način: Zelo pogosti pri več kot 1 od 10 bolnikov
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections.
Prevalenca pridobljene rezistence se lahko pri določenih organizmih razlikuje glede na kraj in čas, lokalni podatki o rezistenci pa so zaželeni, zlasti pri zdravljenju hudih okužb.
For any information about this medicine, please contact the the Marketing Authorisation Holder.
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na imetnika dovoljenja za promet z zdravilom.
Chemical and physical in-use stability has been demonstrated immediately after dilution, after 24 hours at 2-8°C and after 24 hours at room temperature.
Dokazano je, da je raztopina kemijsko in fizikalno stabilna takoj po redčenju, 24 ur, če se hrani pri temperaturi 2-8 °C, in 24 ur, če se hrani pri sobni temperaturi.
In this case you should immediately consult your doctor.
V tem primeru se morate takoj posvetovati z zdravnikom.
The renal clearance constitutes 60%-70% of the total body clearance and is approximately 3 times higher than the creatinine clearance.
Ledvični očistek tvori 60-70 % skupnega očistka in je približno 3-krat večji od kreatininskega očistka.
If one of the above-mentioned situations is applicable to you, your doctor may decide to prescribe you another medicine or to adjust the dose of Ciprofloxacin Hikma or the other medicine.
Če kateri koli od zgoraj omenjenih pogojev velja za vas, vam bo morda zdravnik predpisal drugo zdravilo ali pa vam bo prilagodil odmerek zdravila Ciprofloxacin Hikma ali drugega zdravila.
Determination of serum concentrations, especially of theophylline, and dose adjustments may be necessary.
Morda bo nujno določanje serumskih koncentracij, zlasti teofilina, in prilagajanje odmerkov.
• severe and continuous diarrhoea during treatment, possibly with blood and mucus.
• huda in neprekinjena driska med zdravljenjem, po možnosti s krvjo in sluzjo.
Other specific situations such as osteomyelitis and paediatric patients are stated under Posology.
Drugi posebni primeri, kot so osteomielitis in pediatrični bolniki, so navedeni v tem poglavju.
In order to avoid treatment failure and emergence of resistance it is a prerequisite that patient's compliance and dosing be adequate.
Da bi se izognili neuspehu pri zdravljenju in pojavu odpornosti, je predpogoj za uspešno zdravljenje doslednost bolnika pri jemanju zdravil in ustrezno odmerjanje zdravila.
The duration of treatment depends upon the severity of infection, clinical response and bacteriological findings.
Trajanje zdravljenja je odvisno od stopnje okužbe, kliničnega odziva in rezultatov bakterioloških preizkusov.
Due to the higher plasma levels in the elderly it is advisable to administer a doses based on creatinine clearance and severity of disease.
Zaradi večjih koncentracij v plazmi pri starejših je priporočljivo določiti odmerke na podlagi kreatininskega očistka in stopnje bolezni.
Patients with pre-existent significant renal disorders should be carefully monitored to detect any deterioration in function.
Bolnike z obstoječimi hudimi okvarami ledvic je treba pozorno spremljati, da bi odkrili morebitno poslabšanje delovanja.
During the growth phase of bacteria, a partial rolling up and unfolding of chromosomes takes place.
V fazi rasti bakterije se pojavlja delno zavijanje in odvijanje kromosoma.
In the case of concomitant administration of these products, prothrombin time (PT) or other suitable coagulation tests should be monitored.
Pri sočasni uporabi teh zdravil je treba spremljati protrombinski čas (PČ) ali druge ustrezne teste koagulacije.
An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
Poročali so, da preveliko odmerjanje z odmerkom 12 g povzroča blage simptome toksičnosti.
• allergic reactions after the first administration of this medicine.
• alergijske reakcije po prvem odmerku zdravila.
The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration.
Koncentracija ciprofloksacina v sputumu je 50-70 % koncentracije v serumu.
Very rare: increment of amylase/lipase levels.
Zelo redki: zvišanje ravni amilaz/lipaz.
Prior to initiation of therapy, bacteriological sensitivity tests should be conducted.
Pred začetkom zdravljenja je treba opraviti bakteriološke preizkuse občutljivosti.
Therefore, the serum creatinine concentration must be checked regularly (twice per week) in these patients.
Pri teh bolnikih je zato treba koncentracijo kreatinina v serumu redno pregledovati (dvakrat na teden).
In this case you should immediately consult your doctor, since you may have a severe inflammation of the large intestine (pseudo membranous colitis).
V tem primeru se morate takoj posvetovati z zdravnikom, ker morda imate hudo vnetje debelega črevesa (psevdomembranski kolitis).
- The requested amendments to section 5.1 of the Summary of Product Characteristics including the breakpoints relevant to the indications are acceptable.
- sprejemljivosti vseh zahtevanih dopolnil poglavja 5.1 v Povzetku glavnih značilnosti zdravila, vključno s prelomnimi točkami, ki so pomembne za indikacije,
From the published data, which have demonstrated for the proposed maximum dose 400 mg intravenous three times daily as a maximum dose, a superior prevention of antibiotic resistance without a significant increase in adverse reactions in serious and life-threatening infections of other organ systems, there is no reason to conclude that this favourable risk/benefit profile would differ significantly in the treatment of complicated UTIs.
Na podlagi objavljenih podatkov, ki so za predlagani največji odmerek 400 mg intravensko trikrat dnevno kot največji odmerek dokazali izvrstno sposobnost preprečevanja odpornosti na antibiotike brez znatne ojačitve neželenih reakcij pri resnih in življenjsko nevarnih okužbah drugih organskih sistemov, ne obstaja razloga za zaključek, da bo ta ugoden profil tveganj in koristi znatno drugačen pri zdravljenju zapletenih okužb sečil.
If such reactions occur, a physician must immediately be consulted.
Če se pojavijo take reakcije, se je treba takoj posvetovati z zdravnikom.
The blood level of this medicine can be increased or reduced.
Raven tega zdravila v krvi se lahko poveča ali zmanjša;
Therefore, the use of ciprofloxacin in children is generally not recommended, except for cystic fibrosis patients (see section 4.1).
Zato njegova uporaba pri otrocih na splošno ni priporočena, razen za zdravljenje bolnikov s cistično fibrozo (glejte poglavje 4.1).
In acute and extreme overdosage, reversible kidney damage is seen.
Pri akutnem in ekstremnem prevelikem odmerjanju so opazili reverzibilne poškodbe ledvic.
In patients with severely impaired renal function (creatinine clearance <30 ml/min) the elimination half-life may be prolonged by a factor of 2.
Pri bolnikih s hudo okvaro delovanja ledvic (kreatininski očistek < 30 ml/min) je lahko razpolovni čas izločanja podaljšan za faktor 2.
In case of mixed infections with anaerobes ciprofloxacin must be combined with other antibiotics effective against anaerobes.
Pri mešanih okužbah z anaerobnimi bakterijami je treba ciprofloksacin kombinirati z drugimi antibiotiki, učinkovitimi proti anaerobom.
• methotrexate (used to treat cancer or suppress the immune system).
• metotreksat (uporablja se za zdravljenje raka ali zaviranje imunskega sistema).
These may be manifested as local skin reactions, which rapidly disappear after the infusion has been completed.
Lahko se pojavijo v obliki kožnih reakcij, ki po koncu infundiranja hitro izginejo.
Compatibility with these solutions has been proven in ciprofloxacin concentrations of 1 mg/ml.
Združljivost s temi raztopinami so dokazali pri koncentraciji ciprofloksacina 1 mg/ml.
For more details regarding some of the side effects please see Section 2, ‘Take special care with Ciprofloxacin Hikma- During or after treatment'.
Za dodatne podrobnosti o nekaterih neželenih učinkih glejte poglavje 2, "Bodite posebno pozorni pri uporabi zdravila Ciprofloxacin Hikma - med zdravljenjem ali po njem".
• feeling depressed or confused after administration of Ciprofloxacin Hikma.
• občutek depresije ali zmedenosti po uporabi zdravila Ciprofloxacin Hikma.
Ciprofloxacin is mainly excreted unchanged.
Ciprofloksacin se večinoma izloča nespremenjen.
• In children aged below 5 years
• pri otrocih, mlajših od 5 let;
Rare: transpiration.
Redki: transpiracija.
If necessary, the oral anticoagulant dose should be adjusted as appropriate.
Odmerek antikoagulansa je treba po potrebi prilagoditi.
In this case consult your doctor as your urine needs to be tested.
V tem primeru se posvetujte z zdravnikom, ker bo moral opraviti pregled urina.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF CIPROFLOXACIN HIKMA AND ASSOCIATED NAMES (see Annex I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA CIPROFLOXACIN HIKMA IN Z NJIM POVEZANIH IMEN (glejte Dodatek I)
• cyclosporine (used to prevent rejection reactions after organ transplantations).
• ciklosporin (uporablja se za preprečevanje reakcij po presaditvi organa).
At haemodialysis or peritoneal dialysis only a modest amount of ciprofloxacin (less than 10%) is eliminated.
S hemodializo ali peritonealno dializo se izloči le majhna količina ciprofloksacina (manj kot 10 %).
This has to be taken into consideration for patients on a controlled sodium diet.
To je treba upoštevati pri bolnikih na dieti z malo natrija.
In case of very serious, life-threatening or recurrent infections the dosage can be increased to 400 mg three times daily.
Pri zelo resnih, smrtno nevarnih okužbah ali rekurentnih okužbah, se lahko odmerek poveča na 400 mg trikrat na dan.
The renal clearance occurs through glomerular filtration and active tubular secretion.
Ledvični očistek poteka z glomerularno filtracijo in aktivno tubulno sekrecijo.
Fax: +351 219 615 102 e-mail: geral@hikma.pt
Faks: +351 219 615 102 e-pošta: geral@hikma.pt
If you suffer from dizziness, do not drive or operate machines, which require your full concentration.
Če ste omotični ne vozite avtomobila ali upravljate strojev, pri katerih morate biti popolnoma zbrani.
• crystalluria (presence of crystals in the urine with discomfort when passing urine).
• kristalurija (prisotnost kristalov v urinu in neprijeten občutek med uriniranjem).
This medicinal product is authorised in the Member States of EEA under the following names: Austria - Ciprofloxacin Hikma 200mg/100ml Infusionslösung Germany - Ciprofloxacin Hikma 200mg/100ml Lösung zur Intravenösen Anwendung Ireland - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion Italy - Ciprofloxacin Hikma 200mg/100ml Soluzione per Infusione Endovenosa United Kingdom - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion The Netherlands - Ciprofloxacine Hikma 200mg/100ml Oplossing voor Intraveneuze Infusie
Zdravilo je pridobilo dovoljenje za promet v državah članicah EGP pod naslednjimi imeni: Avstrija - Ciprofloxacin Hikma 200 mg/100 ml Infusionslösung Nemčija - Ciprofloxacin Hikma 200 mg/100 ml Lösung zur Intravenösen Anwendung Irska - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Italija - Ciprofloxacin Hikma 200 mg/100 ml Soluzione per Infusione Endovenosa Velika Britanija - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Nizozemska - Ciprofloxacine Hikma 200 mg/100 ml Oplossing voor Intraveneuze Infusie
They may take the form of local skin reactions, such as reddening of the skin, irritation or pain, which usually disappear quickly after termination of the infusion.
Lahko v obliki lokalnih kožnih reakcij, kot je rdečica kože, draženje ali bolečina, ki ponavadi preneha kmalu po koncu infundiranja.
As with all other antibiotics, the patient should be monitored during therapy for the development of resistant strains of initially sensitive bacteria, especially P. aeruginosa and S. aureus (see the relevant statements in section
Kot pri drugih antibiotikih je treba med zdravljenjem bolnika spremljati zaradi možnosti razvoja rezistentnih sevov sprva občutljivih bakterij, zlasti P. aeruginosa in S. aureus (glejte ustrezne navedbe v poglavju 5.1).
Any unused solution and the vial should be adequately disposed of in accordance with local requirements.
Neuporabljeno raztopino in viale zavrzite v skladu z lokalnimi predpisi.
• If nevertheless complaints occur, such as fever, rash, itching, small red spots on the skin, you should consult your doctor since the treatment may need to be discontinued.
• če se kljub temu pojavijo težave, kot so zvišana telesna temperatura, izpuščaj, srbenje ali majhne rdeče pike na koži, se morate takoj posvetovati z zdravnikom, ker bo morda treba prekiniti zdravljenje;